Overview

Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer

Status:
Active, not recruiting

Trial end date:
2021-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this trial is to evaluate the effect of investigational drug nivolumab in combination with either gemcitabine/cisplatin chemotherapy, or in combination with another investigational agent ipilimumab in patients with advanced unresectable biliary tract cancer. Gemcitabine/cisplatin is the standard of care treatment for biliary tract cancer. Nivolumab and ipilimumab are types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Nivolumab (Opdivo) is FDA approved for the treatment of several cancers including metastatic melanoma, advanced lung, kidney, head & neck and bladder cancer. The combination of nivolumab and ipilimumab (Yervoy) is FDA approved for metastatic melanoma.

Phase:

Phase 2

Details

Lead Sponsor:

University of Michigan Cancer Center
University of Michigan Rogel Cancer Center

Treatments:

Antibodies, Monoclonal
Cisplatin
Gemcitabine
Ipilimumab
Nivolumab